Switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): effects on T-cell compartment and HIV reservoirs

被引：0
|
作者：
Merlini, Esther [1 ]
Cazzaniga, Federico [1 ]
Casabianca, Anna [2 ]
Orlandi, Chiara [2 ]
Ancona, Giuseppe [1 ]
Cogliandro, Viola [1 ]
Tincati, Camilla [1 ]
Bini, Teresa [1 ]
Magnani, Mauro [2 ]
Monforte, Antonella d'Arminio [1 ]
Marchetti, Giulia [1 ]
机构：
[1] Univ Milan, Hlth Sci, Milan, Italy
[2] Univ Urbino Carlo Bo, Dept Biomol Sci, Urbino, Italy
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P100
引用
收藏
页数：3
相关论文
共 50 条
  • [31] HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
    Andreatta, Kristen
    Chang, Silvia
    Martin, Ross
    Acosta, Rima
    Daeumer, Martin
    Thielen, Alexander
    Miller, Michael D.
    White, Kirsten L.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 79 (01) : E47 - E51
  • [32] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response
    Nozza, Silvia
    Poli, Andrea
    Ripa, Marco
    Galli, Laura
    Chiappetta, Stefania
    Spagnuolo, Vincenzo
    Rovelli, Cristina
    Lazzarin, Adriano
    Castagna, Antonella
    Tambussi, Giuseppe
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1549 - 1550
  • [33] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Devred, Ines
    Kayembe, Kick
    Valin, Nadia
    Rougier, Hayette
    Shinga, Bruce Wuembulua
    Lambert-Niclot, Sidonie
    Chiarabini, Thibault
    Meyohas, Marie-Caroline
    Lacombe, Karine
    [J]. BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [34] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Inès Devred
    Kick Kayembe
    Nadia Valin
    Hayette Rougier
    Bruce Wuembulua Shinga
    Sidonie Lambert-Niclot
    Thibault Chiarabini
    Marie-Caroline Meyohas
    Karine Lacombe
    [J]. BMC Infectious Diseases, 23
  • [35] Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients
    Biagi, M.
    Badowski, M. E.
    Chiampas, T.
    Young, J.
    Patel, M.
    Vaughn, P.
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (08) : 766 - 772
  • [36] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [37] Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen
    Brown, Kimberley
    Thomas, David
    McKenney, Kevin
    Reeder, Michael
    Simonson, Richard Bruce
    Bicer, Ceyhun
    Nettles, Richard E.
    Crauwels, Herta
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 541 - 548
  • [38] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    [J]. LANCET HIV, 2019, 6 (10): : E655 - E666
  • [39] Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1
    Negredo, Eugenia
    Clotet, Bonaventura
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 929 - 934
  • [40] Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation
    Singh, Veena Devi
    Singh, Vijay Kumar
    Daharwal, Sanjay J.
    [J]. JOURNAL OF AOAC INTERNATIONAL, 2023, 106 (06) : 1673 - 1681
12345